Enovis Co. (NYSE:ENOV) Receives $67.00 Average PT from Brokerages

Shares of Enovis Co. (NYSE:ENOV) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $67.00.

A number of research analysts have weighed in on the stock. JMP Securities assumed coverage on shares of Enovis in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price target on the stock. Evercore ISI reduced their target price on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research note on Tuesday, October 1st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th.

Institutional Investors Weigh In On Enovis

Institutional investors and hedge funds have recently modified their holdings of the company. Wedge Capital Management L L P NC lifted its stake in Enovis by 16.0% during the fourth quarter. Wedge Capital Management L L P NC now owns 176,962 shares of the company’s stock worth $7,765,000 after purchasing an additional 24,454 shares during the last quarter. Heritage Family Offices LLP increased its holdings in Enovis by 16.6% in the 4th quarter. Heritage Family Offices LLP now owns 5,585 shares of the company’s stock worth $245,000 after buying an additional 794 shares in the last quarter. Pinnacle Bancorp Inc. boosted its stake in shares of Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after buying an additional 300 shares during the last quarter. Park Avenue Securities LLC increased its holdings in Enovis by 12.5% during the fourth quarter. Park Avenue Securities LLC now owns 11,988 shares of the company’s stock valued at $526,000 after buying an additional 1,333 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in Enovis during the fourth quarter valued at about $437,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Trading Up 2.1 %

Enovis stock opened at $45.70 on Thursday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -20.87 and a beta of 1.94. Enovis has a 12 month low of $38.27 and a 12 month high of $65.03. The business has a 50 day moving average price of $45.89 and a two-hundred day moving average price of $44.33.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $505.22 million during the quarter, compared to analysts’ expectations of $504.44 million. During the same quarter in the previous year, the company posted $0.56 EPS. Enovis’s revenue was up 21.0% on a year-over-year basis. As a group, equities analysts forecast that Enovis will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.